Literature DB >> 11510276

Treatment options for encapsulating peritoneal sclerosis based on progressive stage.

H Kawanishi1, Y Harada, T Noriyuki, T Kawai, S Takahashi, M Moriishi, S Tsuchiya.   

Abstract

Sclerosing encapsulating peritonitis (SEP) is recognized as a serious complication of peritoneal dialysis. However, recovery is possible if an appropriate diagnosis and treatment are made. The term SEP is used most often, but is inaccurate, particularly the reference to peritonitis. A more accurate description would be "encapsulating peritoneal sclerosis" (EPS). From the therapeutic perspective, the diagnosis should be established before EPS develops. Early diagnosis is important. Furthermore, it is also important to determine the therapeutic tactics for EPS according to the disease stage. Most cases of EPS develop with manifestations of fever, increased levels of C-reactive protein (CRP), and slight ileus symptoms, accompanied by increased ascites ("inflammatory stage"). Following precise identification of the inflammatory stage, steroid administration should be initiated immediately with the onset of EPS. Methylprednisolone pulse therapy is recommended during the early stage. If the EPS is not relieved, or if it recurs within 1 month, the steroid dose should be decreased and the patient should be managed by total parenteral nutrition (TPN) ("encapsulating stage"). If ileus symptoms remain despite the absence of inflammatory findings and decreased ascites, laparotomy and enterolysis should be considered within 6 months ("ileus stage"). However, it is important that the enterolysis be performed without damaging the capsule-covered intestine. To date, we have successfully treated EPS in 18 of 19 patients using these options. In 3 patients, EPS was relieved by steroid administration. In 15 patients, EPS was relieved by total intestinal enterolysis. Enterolysis patients had satisfactory operative outcomes and eventually returned to their previous social activities. One patient experienced perforation of the small intestine and pan-peritonitis, and died of sepsis. In summary, EPS is not an incurable disease. It can be completely overcome by active diagnosis and treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11510276

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  10 in total

1.  Chronic abdominal pain in a patient on chronic peritoneal dialysis: answer.

Authors:  Olivera Marsenic; Bernard Kaplan; Kevin E C Meyers
Journal:  Pediatr Nephrol       Date:  2008-07-09       Impact factor: 3.714

2.  The peritoneal sieving of sodium: a simple and powerful test to rule out the onset of encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis.

Authors:  Vincenzo La Milia; Selena Longhi; Elisabetta Sironi; Giuseppe Pontoriero
Journal:  J Nephrol       Date:  2016-12-24       Impact factor: 3.902

3.  mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience.

Authors:  Maria Messina; Claudia Ariaudo; Alberto Mella; Vincenzo Cantaluppi; Giuseppe P Segoloni; Luigi Biancone
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

4.  Transcriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis.

Authors:  Fabian R Reimold; Niko Braun; Zsuzsanna K Zsengellér; Isaac E Stillman; S Ananth Karumanchi; Hakan R Toka; Joerg Latus; Peter Fritz; Dagmar Biegger; Stephan Segerer; M Dominik Alscher; Manoj K Bhasin; Seth L Alper
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

5.  C-reactive protein levels in combination with abdominal CT scans is a useful tool to predict the macroscopic appearance in late-stage EPS patients prior to surgery.

Authors:  Daniel Kitterer; Stephan Segerer; Wolfgang Steurer; Juergen Dippon; Angela Geissler; Christoph Ulmer; Niko Braun; Mark Dominik Alscher; Joerg Latus
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-08-13

Review 6.  Surgical management of Encapsulating Peritoneal Sclerosis (EPS) in children: international case series and literature review.

Authors:  Videha Sharma; Zia Moinuddin; Angela Summers; Mohan Shenoy; Nicholas Plant; Semir Vranic; Agnieszka Prytula; Zlatan Zvizdic; Vasiliki Karava; Nikoleta Printza; John Vlot; David van Dellen; Titus Augustine
Journal:  Pediatr Nephrol       Date:  2021-08-26       Impact factor: 3.714

7.  A case of fulminant sclerosing peritonitis presented like acute culture-negative peritonitis and successfully treated with corticosteroid therapy.

Authors:  Ji Yun Jung; Jong Tae Cho
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

8.  Post-transplantation encapsulating peritoneal sclerosis without inflammation or radiological abnormalities.

Authors:  Sayed Meelad Habib; Frank Johan Marinus Frederik Dor; Mario Richard Korte; Sander Martijn Hagen; Michiel Gerardus Henricus Betjes
Journal:  BMC Nephrol       Date:  2013-09-26       Impact factor: 2.388

Review 9.  Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review.

Authors:  Katsushi Takebayashi; Hiromichi Sonoda; Tomoharu Shimizu; Hiroyuki Ohta; Mitsuaki Ishida; Eiji Mekata; Yoshihiro Endo; Tohru Tani; Masaji Tani
Journal:  BMC Surg       Date:  2014-08-27       Impact factor: 2.102

Review 10.  Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

Authors:  Rajesh M Jagirdar; Andreas Bozikas; Sotirios G Zarogiannis; Maria Bartosova; Claus Peter Schmitt; Vassilios Liakopoulos
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.